Scheitzach Judith, Schebesch Karl-Michael, Brawanski Alexander, Proescholdt Martin A
Department of Neurosurgery, University of Regensburg Medical Center, Franz Josef Strauß Allee 11, 93053, Regensburg, Germany.
J Neurooncol. 2014 Jan;116(2):381-6. doi: 10.1007/s11060-013-1309-x. Epub 2013 Nov 21.
Microsurgical resection is the primary treatment of skull base meningiomas. Maximal resection provides the best tumor control rates but can be associated with high surgical morbidity. To understand the relation between extent of resection (EOR) and functional outcome we have analyzed the neurological improvement and recurrence rate in a large consecutive series of skull base meningioma patients. In addition, we defined anatomical and biological factors predictive for recurrence and overall outcome. We investigated 226 skull base meningioma patients receiving tumor resection in our institution. The most frequent location was the medial sphenoid ridge (29.6 %). EOR was rated according to the Simpson scale. Overall performance was measured by the Karnofsky performance score (KPS); neurological deficits were quantified using the Medical Research Council Neurological Severity Score (MRC-NPS). Complete resection was achieved in 62.8 % and the EOR was significantly correlated to tumor location. The morbidity and mortality rate was 32.1 and 2.7 % respectively, new permanent neurological deficits occurred in 3.5 % of all patients. From all patients with focal neurological deficits, 60.1 % experienced significant improvement. Both the MRC-NPS and the KPS significantly improved from the preoperative status to discharge, however the improvement rate was dependent on the tumor location. Recurrence rate was 15.5 %; tumor size, bone- and venous sinus infiltration, WHO grade, poor EOR but not MIB-1 labeling index were independent factors predictive for recurrence. Microsurgical resection of skull base meningiomas improves neurological impairment in the majority of patients. Specific risk factors for recurrence require consideration for postoperative management.
显微手术切除是颅底脑膜瘤的主要治疗方法。最大程度切除可提供最佳的肿瘤控制率,但可能伴有较高的手术并发症发生率。为了解切除范围(EOR)与功能预后之间的关系,我们分析了一大组连续的颅底脑膜瘤患者的神经功能改善情况和复发率。此外,我们确定了预测复发和总体预后的解剖学和生物学因素。我们调查了在我院接受肿瘤切除的226例颅底脑膜瘤患者。最常见的部位是蝶骨嵴内侧(29.6%)。根据辛普森量表对EOR进行评分。总体表现通过卡诺夫斯基表现评分(KPS)来衡量;使用医学研究委员会神经严重程度评分(MRC-NPS)对神经功能缺损进行量化。62.8%的患者实现了完全切除,EOR与肿瘤位置显著相关。发病率和死亡率分别为32.1%和2.7%,3.5%的患者出现了新的永久性神经功能缺损。在所有有局灶性神经功能缺损的患者中,60.1%的患者有显著改善。从术前状态到出院,MRC-NPS和KPS均有显著改善,但改善率取决于肿瘤位置。复发率为15.5%;肿瘤大小、骨质和静脉窦浸润、世界卫生组织分级、EOR不佳但不是MIB-1标记指数是预测复发的独立因素。颅底脑膜瘤的显微手术切除可改善大多数患者的神经功能障碍。复发的特定危险因素在术后管理中需要考虑。